Humoral response to <scp>BNT162b2 mRNA COVID</scp>‐19 vaccine in peritoneal and hemodialysis patients: A comparative study

Duarte, Rui A; Roldão, Marisa; Figueiredo, Cátia; Luz, Ivan; Ferrer, Francisco; Gonçalves, Hernâni; Sofia, Flora; Lopes, Karina

doi:10.1111/1744-9987.13766

Cited by 11 publications

(14 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are previous contradictory results regarding this issue. While some authors, including ourselves, could not find an association between these variables and the anti-S-RBD IgG titers [ 24 ], other studies suggest that less comorbidity presence leads to a higher anti-S-RBD IgG titer [ 19 , 23 ]. It is worthy to note that a recent study performed in hemodialysis patients also failed to detect an association between COVID-19 severity and obesity, diabetes, or comorbidity presence [ 3 ], factors that do have an impact on disease severity in the overall population.…”

Section: Discussionmentioning

confidence: 89%

Assessment of the humoral response to the homologous Gam-COVID-Vac (Sputnik V) or heterologous Sputnik V/mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in dialysis patients

et al. 2022

View full text Add to dashboard Cite

Background and Aim Dialysis patients are a high-risk population and have a reduced immune response to vaccination against SARS-CoV-2. The aim of this study was to assess the humoral response to homologous Gam-COVID-Vac (Sputnik V) and heterologous Sputnik V/mRNA-1273 (Moderna) vaccination in dialysis patients. The vaccination scheme depended on dose availability and the prioritization of risk populations as established by the Argentine Ministry of Health. Methods Previous COVID-19 infection was determined in symptomatic patients. Binding IgG antibodies against the spike (S) receptor-binding domain (RBD) of SARS-CoV-2 (anti-S-RBD) concentration was assessed between 3 and 16 weeks after the boost dose. Anti-S-RBD antibodies were quantified using the Abbott Diagnostics SARS-CoV-2 IgG II Quant chemiluminescent microparticle immunoassay (CMIA) on an Architect i2000 SR and an Alinity I analyzer (Abbott Diagnostics, Abbott Park, Illinois, USA). To standardize the results to WHO binding antibody units (BAU), a correction factor for Abbott arbitrary units (AU) was applied where 1 BAU/mL equals 0.142 AU, as previously established by Abbott with the WHO international standard NIBSC 20–136. Following the manufacturer’s recommendations, samples were considered reactive for anti-S-RBD when titers were above 50 AU/mL (7.2 BAU/mL). An 80% protective effect (PROT-80) against symptomatic SARS-CoV-2 infection was assumed when anti-S-RBD titers were 506 BAU/ml or higher. Charlson Comorbidity Index (CCI) score was classified as mild = 1–2, moderate = 3–4, and severe ≥ 5. Side effects were evaluated until day 7 by patients´ self-reported questionnaire. Results One hundred seven participants were enrolled [ n = 84 homologous (SpV/SpV), nn 23 heterologous (SpV/Mod)]. Median (IQR) age was 64 (50–75) years old and 79 (73.8%) were male. Additionally, 19 (22.6%) of the SpV/SpV and 4 (17.4%) of the SpV/Mod group had a prior confirmed SARS-CoV-2 infection ( p = 0.589). In the overall population, 103 patients reached seroconversion (96.3%). Anti-S-RBD IgG median titers (IQR) were higher in the heterologous [1222 (288–5680) BAU/mL] than in the homologous scheme [447 (100–1551) BAU/mL], p = 0.022. In a linear model adjusted for age, gender, days from first vaccination to boost dose and days from the boost dose to the anti-S-RBD IgG determination, previous SARS-COV-2 infection (B: 2062.2; CI95: 1231.8–2892.6; p < 0.001), and SpV/Mod vaccination scheme (B: 1294.6; CI95: 435.58–2147.6; p = 0.003) were independently associated with anti-S-RBD levels. Finally, a higher frequency of adverse effects was associated with the heterologous scheme, although they were well tolerated by all individuals. Conclusions The present study provides evidence that the homologous SpV/SpV and heterologous SpV/Mod schemes showed good e...

show abstract

Section: Discussionmentioning

confidence: 89%

Assessment of the humoral response to the homologous Gam-COVID-Vac (Sputnik V) or heterologous Sputnik V/mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in dialysis patients

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Meanwhile, the results for mRNA COVID-19 vaccines, including BNT162b2 and mRNA-1273, were inconclusive. Some studies claimed that BNT162b2 had favorable immunogenicity in ESRD patients on hemodialysis [38][39][40][41], while others found it to have low yet adequate immuno-genicity [26,27,[42][43][44][45][46][47]. A multicenter cohort study in ESRD with hemodialysis patients found that two doses of mRNA-1273 were more immunogenic than BNT162b2 [48,49].…”

Section: Discussionmentioning

confidence: 99%

ChAdOx1 nCoV-19 Immunogenicity and Immunological Response Following COVID-19 Infection in Patients Receiving Maintenance Hemodialysis

et al. 2022

View full text Add to dashboard Cite

Patients with end-stage renal disease (ESRD) receiving hemodialysis (HD) were found to have a decreased immune response following mRNA COVID-19 immunization. ChAdOx1 nCoV-19 was a promising COVID-19 vaccine that performed well in the general population, but the evidence on immunogenicity in ESRD with HD patients was limited. Moreover, the immunological response to COVID-19 infection was inconclusive in patients with ESRD and HD. The aim of this study was to investigate the immunogenicity of ChAdOx1 nCoV-19 vaccination and the immunological response after COVID-19 infection in ESRD patients with HD. The blood samples were obtained at baseline, 1-month, and 3-month follow-up after each shot or recovery. All participants were measured for anti-spike IgG by the ELISA method, using Euroimmun. This study found a significant increase in anti-spike IgG after 1 month of two-shot ChAdOx1 nCoV-19 vaccination, followed by a significant decrease after 3 months. On the other hand, the anti-spike IgG was maintained in the post-recovery group. There was no significant difference in the change of anti-spike IgG between the one-shot ChAdOx1 nCoV-19-vaccinated and post-recovery groups for both 1-month and 3-month follow-ups. The seroconversion rate for the vaccinated group was 60.32% at 1 month after one-shot vaccination and slightly dropped to 58.73% at the 3-month follow-up, then was 92.06% at 1 month after two-shot vaccination and reduced to 82.26% at the 3-month follow-up. For the recovered group, the seroconversion rate was 95.65% at 1 month post-recovery and 92.50% at 3-month follow-up. This study demonstrated the immunogenicity of two-dose ChAdOx1 nCoV-19 in ESRD patients with HD for humoral immunity. After COVID-19 infection, the humoral immune response was strong and could be maintained for at least three months.

show abstract

“…It is tempting to speculate that markers of immunosenescence may be better predictors of the immune response than chronological age per se. Antibody titers were numerically higher in peritoneal dialysis than in hemodialysis patients in some [72][73][74] , but not all studies 75,76 .…”

Section: Humoral Responsementioning

confidence: 94%

COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment

Karoui

Vriese

2022

Kidney International

104

View full text Add to dashboard Cite

Humoral response to BNT162b2 mRNA COVID‐19 vaccine in peritoneal and hemodialysis patients: A comparative study

Cited by 11 publications

References 45 publications

Assessment of the humoral response to the homologous Gam-COVID-Vac (Sputnik V) or heterologous Sputnik V/mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in dialysis patients

Assessment of the humoral response to the homologous Gam-COVID-Vac (Sputnik V) or heterologous Sputnik V/mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in dialysis patients

ChAdOx1 nCoV-19 Immunogenicity and Immunological Response Following COVID-19 Infection in Patients Receiving Maintenance Hemodialysis

COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment

Contact Info

Product

Resources

About